Study Summaries

Avutometinib 3.2 mg BIW + defactinib 200 mg BID (3-weeks-on/1-week-off) produced clinically meaningful and durable responses with manageable toxicity in recurrent LGSOC

Camrelizumab plus famitinib significantly improves response rate and survival outcomes compared to camrelizumab alone or chemotherapy in pretreated R/M CC with a manageable safety profile.

Relacorilant plus nab-paclitaxel significantly prolonged PFS and showed a clinically meaningful interim OS improvement versus nab-paclitaxel alone, with manageable toxicity, positioning the combination as a potential new standard for platinum-resistant ovarian cancer.

Olaparib significantly improved PFS and ORR over nonplatinum chemotherapy, though no OS benefit was observed in the overall population. In patients with ≥3 prior therapies, chemotherapy had more favorable OS.

The addition of durvalumab with olaparib and cediranib did not improve PFS in platinum-resistant ovarian cancer patients with prior bevacizumab exposure.

The combination of palbociclib and letrozole significantly improved PFS compared to placebo with letrozole. However, it was associated with higher hematologic toxicities, particularly neutropenia.

The combination of abemaciclib and fulvestrant shows promising efficacy and manageable toxicity in HR-positive advanced or recurrent endometrial cancer, especially in CN-L/NSMP tumors

First-line lenvatinib plus pembrolizumab did not significantly improve PFS or OS compared to chemotherapy in mismatch repair-proficient (pMMR) advanced endometrial cancer. Toxicity was higher in the experimental arm but manageable. dMMR exploratory analysis shows promise in this subgroup.